English English | 中文 中文

Recent Liver Research Articles

Recently published articles from Liver Research.

Dysregulation of glutathione synthesis in liver disease

Available online 11 June 2020
Shelly C. Lu

Glutathione (GSH), a tripeptide that is present in all mammalian tissues, is especially highly concentrated in the liver. GSH synthesis occurs via two adenosine triphosphate (ATP)-requiring enzymatic...

MiR-22 as a metabolic silencer and liver tumor suppressor

Available online 9 June 2020
Lijun Wang | Yu-Shiuan Wang | Eko Mugiyanto | Wei-Chiao Chang | Yu-Jui Yvonne Wan

With obesity rate consistently increasing, a strong relationship between obesity and fatty liver disease has been discovered. More than 90% of bariatric surgery patients also have non-alcoholic fatty...

Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis

Available online 3 June 2020
John Y.L. Chiang | Jessica M. Ferrell

Cholesterol 7 alpha-hydroxylase (CYP7A1, EC1.14) is the first and rate-limiting enzyme in the classic bile acid synthesis pathway. Much progress has been made in understanding the transcriptional regulation...

Efficacy and safety of direct-acting antiviral agent regimens in a real-world cohort of adult Chinese patients with chronic hepatitis C virus infection

Available online 3 June 2020
Jinyuan Wei | Yongyu Mei | Jianping Li | Jing Yuan | Xiaohua Yang | Zhen Xu | Guoli Lin | Juan Zhang | Zhixin Zhao | Xiaohong Zhang

To investigate the safety and efficacy of direct-acting antiviral (DAA) regimens in a cohort of Chinese patients with chronic hepatitis C virus (HCV) infection....

The metabolite, alpha-ketoglutarate inhibits non-alcoholic fatty liver disease progression by targeting lipid metabolism

Available online 7 May 2020
Katsuya Nagaoka | Joud Mulla | Kevin Cao | Zhixiang Cheng | Dan Liu | William Mueller | Amalia Bay | Grace Hildebrand | Shaolei Lu | Chiung-Kuei Huang

Non-alcoholic liver disease is of increased concern and contributing to economic burdens not only in developing countries but in developed countries as well. Identifying the biomarker of early diagnosis...

Intestinal barrier function and metabolic/liver diseases

Available online 6 April 2020
Siddhartha S. Ghosh | Jing Wang | Paul J. Yannie | Shobha Ghosh

Dietary, environmental or genetic changes contribute to the development of several metabolic and neurological diseases. Extensive research efforts have been directed towards examining how these factors...

Functional cure of chronic hepatitis B: Efforts and prospects

March 2020
Zhishuo Mo | Weiqiang Gan | Qiyi Zhao | Yalin Yin | Zhiliang Gao

Nutrient mTORC1 signaling contributes to hepatic lipid metabolism in the pathogenesis of non-alcoholic fatty liver disease

March 2020
Hanqing Chen

Energy metabolism is maintained by the complex homeostatic system in multiple cells and organs involving “nutrient signaling” or “nutrient sensor”. Overnutrient-induced chronic metabolic diseases, as...

The expression status of ZIC2 is an independent prognostic marker of hepatocellular carcinoma

March 2020
Qinglei Kong | Wenchao Li | Pan Hu | Hua Zeng | Yuhang Pan | Taicheng Zhou | Kunpeng Hu

Zinc finger protein of cerebellum 2 (ZIC2) is a transcriptional activator or repressor that is important for the organogenesis of the central nervous system. Previous studies have reported that ZIC2...

The alteration of immune cells in the pathogenesis of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

March 2020
Dechun Feng

The prevalence of non-alcoholic fatty liver disease (NAFLD) increases rapidly in recent decades. NAFLD has become a major public health problem in China and the whole world, and it is considered as...

Lipid and energy metabolism in Wilson disease

March 2020
Tagreed A. Mazi | Noreene M. Shibata | Valentina Medici

Copper accumulation and deficiency are reciprocally connected to lipid metabolism. In Wilson disease (WD), which is caused by a genetic loss of function of the copper-transporting P-type ATPase beta,...

Functional roles of CCL5/RANTES in liver disease

March 2020
Lili Chen | Qianfei Zhang | Chang Yu | Fang Wang | Xiaoni Kong

Inflammation, which is mediated by leukocyte trafficking and activation, plays a prominent role in the pathogenesis of acute and chronic liver injury. Chemokines are critical mediators involved in the...

The roles of zinc finger proteins in non-alcoholic fatty liver disease

March 2020
Guoqiang Li | Xinran Ma | Lingyan Xu

Non-alcoholic fatty liver disease (NAFLD) is a common chronic disease characterized by excessive fat accumulation in hepatocytes in the absence of alcohol consumption. Modern trends towards excessive...

Nuclear receptors and non-alcoholic fatty liver disease: An update

Available online 15 March 2020
Xiao Yang | Frank J. Gonzalez | Min Huang | Huichang Bi

Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver disease in adults and children worldwide. The symptoms of NAFLD range from simple steatosis and non-alcoholic...

Inhibition of mitochondrial fatty acid oxidation in drug-induced hepatic steatosis

December 2019
Bernard Fromenty

Mitochondrial fatty acid oxidation (mtFAO) is a key metabolic pathway required for energy production in the liver, in particular during periods of fasting. One major consequence of drug-induced impairment...

Structural perspectives of the CYP3A family and their small molecule modulators in drug metabolism

December 2019
William C. Wright | Jude Chenge | Taosheng Chen

Cytochrome P450 (CYP) enzymes function to catalyze a wide range of reactions, many of which are critically important for drug response. Members of the human cytochrome P450 3A (CYP3A) family are particularly...

Microbiome dysbiosis and alcoholic liver disease

December 2019
Fengyuan Li | Craig J. McClain | Wenke Feng

Microbiome dysbiosis is strongly associated with alcoholic liver disease (ALD). Recent studies on comprehensive analyses of microbiome compositional and functional changes have begun to uncover the...

Lipid droplet dynamics in alcoholic fatty liver disease

December 2019
Ryan J. Schulze | Wen-Xing Ding

The rising incidence of alcohol-related liver disease (ALD) demands making urgent progress in understanding the fundamental molecular basis of alcohol-related hepatocellular damage. One of the key early...

Necroptosis in ischemia-reperfusion injury of lean and steatotic livers

December 2019
Hua Sun | Tara McKeen | Hua Wang | Hong-Min Ni

Hepatic ischemia-reperfusion (IR) injury is a major complication during liver transplantation, liver resection, and other clinical situations. Increased hepatic IR injury in steatotic livers is a major...

The interplay between hepatocyte nuclear factor 4α (HNF4α) and cholesterol sulfotransferase (SULT2B1b) in hepatic energy homeostasis

December 2019
Yuhan Bi | Youya Wang | Wen Xie

The nuclear receptor hepatocyte nuclear factor 4alpha (HNF4α) plays a critical role in the regulation of metabolic homeostasis, including glucose homeostasis. Sulfotransferases (SULTs) catalyze the...

Dietary fatty acids and bioactive fatty acid metabolites in alcoholic liver disease

December 2019
Kara H. Zirnheld | Dennis R. Warner | Jeffrey B. Warner | Josiah E. Hardesty | Craig J. McClain | Irina A. Kirpich

Alcoholic liver disease (ALD) comprises a spectrum of liver pathology, including steatosis, steatohepatitis, and cirrhosis. Previous work from our group and others suggests that dietary fat, both the...

Mitochondrial damage and biogenesis in acetaminophen-induced liver injury

December 2019
Hartmut Jaeschke | Luqi Duan | Nga T. Nguyen | Anup Ramachandran

Liver injury and acute liver failure caused by acetaminophen (APAP) overdose is the clinically most important drug toxicity in Western countries. Mechanistic investigations have revealed a central role...

Lysosome and proteasome dysfunction in alcohol-induced liver injury

December 2019
Terrence M. Donohue | Natalia A. Osna | Kusum K. Kharbanda | Paul G. Thomes

The review describes research findings on the influence of alcohol consumption on two crucial catabolic systems in hepatocytes: the lysosome and the ubiquitin-proteasome system (UPS). The lysosome is...

LncRNA RP11-307C12.11 promotes the growth of hepatocellular carcinoma by acting as a molecular sponge of miR-138

December 2019
Yinan Deng | Yusheng Cheng | Kaining Zeng | Haibo Li | Yiming Huang | Yiquan Jiang | Tingting Xia | Tong Zhang | Yang Yang

Abnormal expression of long non-coding RNAs (lncRNAs) has been found in almost all tumors in humans, providing numerous potential diagnostic and prognostic biomarkers, and therapeutic targets....

A scoring model based on plasma fibrinogen concentration for predicting recurrence of hepatocellular carcinoma after liver transplantation

December 2019
Kai-Ning Zeng | Ying-Cai Zhang | Gen-Shu Wang | Jian Zhang | Yi-Nan Deng | Shi-Hui Li | Qi Zhang | Hua Li | Guo-Ying Wang | Yang Yang | Gui-Hua Chen

We investigated the prognostic value of preoperative fibrinogen levels in hepatocellular carcinoma patients receiving liver transplantation by building a scoring model for predicting tumor recurren...

Hepatic macrophages in drug-induced liver injury

December 2019
Zhao Shan | Cynthia Ju

Drug-induced liver injury (DILI) is a major public health concern. Intrinsic DILI, for example, acetaminophen overdose accounts for half of acute liver failure in the United States. However, the most...

Pyrrolizidine alkaloids: An update on their metabolism and hepatotoxicity mechanism

December 2019
Jie Xu | Weiqian Wang | Xiao Yang | Aizhen Xiong | Li Yang | Zhengtao Wang

Pyrrolizidine alkaloids (PAs) are among the most hepatotoxic natural compounds that are widely distributed throughout the world. Most PAs are metabolically activated to trigger toxicity. Exposure to...

Emerging role of the orphan nuclear receptor estrogen-related receptor gamma in liver metabolic diseases

June 2019
Don-Kyu Kim | Hueng-Sik Choi

Estrogen-related receptor gamma (ERRγ) is one of three members of the ERR family and remains an orphan, as there are no known natural ligands. ERRγ is an inducible transcription factor, and its ligand-independent...

Risk assessment and management of hepatitis B reactivation from direct-acting antivirals for hepatitis C

June 2019
Maureen Whitsett | David M. Feldman | Calvin Q. Pan

Although hepatitis B virus (HBV) reactivation has been reported in hepatitis C patients who received interferon therapy, rare cases of HBV reactivation occur in the context of direct-acting antiviral...

Biliary endoscopy in the management of primary sclerosing cholangitis and its complications

June 2019
Brian M. Fung | James H. Tabibian

Primary sclerosing cholangitis (PSC) is a chronic, idiopathic, cholestatic liver disease characterized by inflammation and fibrosis of the intrahepatic and/or extrahepatic bile ducts. It can affect...

Functions of hepatic non-parenchymal cells in alcoholic liver disease

June 2019
Won-Mook Choi | Myung-Ho Kim | Won-Il Jeong

Alcoholic liver disease (ALD) represents a wide spectrum of disease from simple steatosis to cirrhosis. Although there have been multiple attempts to treat ALD, its treatment is still based on abstinence...

The acidic pathway of bile acid synthesis: Not just an alternative pathway

June 2019
William M. Pandak | Genta Kakiyama

Over the last two decades, the prevalence of obesity, and metabolic syndromes (MS) such as non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM), have dramatically increased....

Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist

June 2019
Adnan Malik | Ani A. Kardashian | Kais Zakharia | Christopher L. Bowlus | James H. Tabibian

Cholestatic liver diseases (CLDs) encompass a variety of disorders of abnormal bile formation and/or flow. CLDs often lead to progressive hepatic insult and injury and following the development of cirrhosis...

Functional roles of gut bacteria imbalance in cholangiopathies

March 2019
Keisaku Sato | Fanyin Meng | Giammarco Fava | Shannon Glaser | Gianfranco Alpini

Cholangiopathies are caused by bile duct damage or inflammation followed by cholestasis leading to liver fibrosis. Bile duct epithelial cells, cholangiocytes, are a primary target for cholangiopathies....

Bile acid receptors and gastrointestinal functions

March 2019
Alexander L. Ticho | Pooja Malhotra | Pradeep K. Dudeja | Ravinder K. Gill | Waddah A. Alrefai

Bile acids modulate several gastrointestinal (GI) functions including electrolyte secretion and absorption, gastric emptying, and small intestinal and colonic motility. High concentrations of bile acids...

Endoplasmic reticulum stress and liver diseases

March 2019
Xiaoying Liu | Richard M. Green

Endoplasmic reticulum (ER) stress occurs when ER homeostasis is perturbed with accumulation of unfolded/misfolded protein or calcium depletion. The unfolded protein response (UPR), comprising of inositol-requiring...

Chlorpromazine protects against acetaminophen-induced liver injury in mice by modulating autophagy and c-Jun N-terminal kinase activation

March 2019
Yuan Li | Hong-Min Ni | Hartmut Jaeschke | Wen-Xing Ding

Overdose of acetaminophen (APAP) leads to liver injury, which is one of the most common causes of liver failure in the United States. We previously demonstrated that pharmacological activation of autophagy...

Role of gut microbiota in the development of non-alcoholic fatty liver disease

March 2019
Xuemei Wang | Jialin Xia | Changtao Jiang

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease characterized by hepatic steatosis in the absence of other causes, such as chronic alcohol consumption, that cause secondary hepatic...

The role of gut microbiota in liver disease development and treatment

March 2019
Lijun Wang | Yu-Jui Yvonne Wan

Liver cancer is the sixth most common cancer worldwide, and the third most common cause of cancer-related death. Hepatocellular carcinoma (HCC), which accounts for more than 90% of primary liver cancers,...

Altered gut-liver axis in liver diseases

March 2019
Huiping Zhou | Jasmohan S. Bajaj | Grace L. Guo

Alcoholic liver disease and mast cells: What's your gut got to do with it?

March 2019
Julie Ann Tolefree | Abigail Joy Garcia | Jenee Farrell | Vik Meadows | Lindsey Kennedy | Laura Hargrove | Jennifer Demieville | Nicole Francis | Julia Mirabel | Heather Francis

Alcoholic liver disease (ALD) remains one of the leading causes of liver injury and death when left untreated. The gut microbiota has been recognized as a key regulator of a number of pathologies, including...

Sphingosine-1-phosphate signaling and the gut-liver axis in liver diseases

March 2019
Eric K. Kwong | Huiping Zhou

The liver is the central organ involved in lipid metabolism and the gastrointestinal (GI) tract is responsible for nutrient absorption and partitioning. Obesity, dyslipidemia and metabolic disorders...

Alcoholic liver disease: A current molecular and clinical perspective

December 2018
Koichiro Ohashi | Michael Pimienta | Ekihiro Seki

Heavy alcohol use is the cause of alcoholic liver disease (ALD). The ALD spectrum ranges from alcoholic steatosis to steatohepatitis, fibrosis, and cirrhosis. In Western countries, approximately 50%...

Hemobilia: Etiology, diagnosis, and treatment

December 2018
Rani Berry | James Han | Ani A. Kardashian | Nicholas F. LaRusso | James H. Tabibian

Hemobilia refers to bleeding from and/or into the biliary tract and is an uncommon but important cause of gastrointestinal hemorrhage. Reports of hemobilia date back to the 1600s, but due to its relative...

Share this page: